Inhalation Drug Delivery Market Size, Share, Opportunities, And Trends By Technology (Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer, Liquid Inhaler), By Application (Disease Treatment, Research/Academic Purposes) And Geography - Forecasts From 2019 To 2024
- Published : Apr 2021
- Report Code : KSI061614739
- Pages : 118
The inhalation drug delivery market is expected to grow at a CAGR of 3.58% by the end of 2024. Inhalation drug delivery is referred to the transfer of drugs into the human body through the lungs or it is also known as the pulmonary route of administration. These are available in either liquid or in powdered form. The market is poised to grow during the forecast period owing to the prevalence of asthma and COPD (Chronic Obstructive Pulmonary Disease). Furthermore, the growing geriatric population and growing health expenditure are emanating the market growth during the forecast period. Technological advancements will provide an opportunity for the growth of the global inhalation drug delivery market in the forecast period and beyond.
DRIVERS
Prevalence of Chronic Obstructive Pulmonary Disease, COPD.
Growing Geriatric Population.
Increasing health expenditure worldwide.
RESTRAINTS
Stringent regulations regarding approval of medical devices.
INDUSTRY UPDATE
On April 12, 2017, Respira Therapeutics, Inc. entered into a strategic collaboration with the United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234™ for pulmonary hypertension in the North American region.
On March 8, 2017, Breath Therapeutics BV, company developing advanced drug-aerosol therapeutics for pulmonary orphan indications announced the closing of a US$46 million series A financing. The company has planned to conduct phase 3 trials in Europe and the United States followed by the submission for market approval, and further commercialization.
The major players profiled in the inhalation drug delivery market include GlaxoSmithKline group of companies, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Gerresheimer AG, Medisol Lifescience Pvt. Ltd, Cipla Limited, and H&T Presspart Manufacturing Ltd.
Segmentation
The inhalation drug delivery market has been analyzed through the following segments:
By Technology
Dry powder inhaler
Metered dose inhaler
Nebulizer
Liquid inhaler
By Application
Disease Treatment
Research/Academic purposes
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. INHALATION DRUG DELIVERY MARKET BY TECHNOLOGY
5.1. Dry powder inhaler
5.2. Metered dose inhaler
5.3. Nebulizer
5.4. Liquid inhaler
6. INHALATION DRUG DELIVERY MARKET BY APPLICATION
6.1. Disease Treatment
6.2. Research/Academic purposes
7. INHALATION DRUG DELIVERY MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. United Kingdom
7.3.2. Germany
7.3.3. France
7.3.4. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. UAE
7.4.3. Israel
7.4.4. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. India
7.5.3. Australia
7.5.4. South Korea
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Company Benchmarking and Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. GlaxoSmithKline group of companies
9.2. Merck & Co., Inc.
9.3. AstraZeneca
9.4. Boehringer Ingelheim International GmbH
9.5. Gerresheimer AG
9.6. Medisol Lifescience Pvt. Ltd
9.7. Cipla Limited
9.8. H&T Presspart Manufacturing Ltd.
LIST OF FIGURES
LIST OF TABLES
GlaxoSmithKline group of companies
AstraZeneca
Boehringer Ingelheim International GmbH
Gerresheimer AG
Medisol Lifescience Pvt. Ltd
Cipla Limited
H&T Presspart Manufacturing Ltd.
Related Reports
Report Name | Published Month | Get Sample PDF |
---|---|---|
Pulmonary Drug Delivery Systems Market Growth: Report, 2021 - 2026 | Aug 2021 | |
Drug Delivery Polymer Market Size & Share: Report, 2023-2028 | Sep 2023 | |
Injectable Drug Delivery Market Share: Industry Report, 2019-2024 | May 2020 | |
Nasal Drug Delivery Market Size & Share: Industry Report, 2019-2024 | Mar 2021 | |
Oral Drug Delivery Market Share: Industry Report, 2022-2027 | Apr 2022 |